Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.32 |
| ▸ | EYA2 | O00167 | 1/20 | 0.32 |
| ▸ | APP | P05067 | 1/20 | 0.32 |
| ▸ | ACE | P12821 | 1/20 | 0.32 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.31 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.31 |
| ▸ | HMGCR | P04035 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13888871 | 0.83 | ALDH1A1 (0.32) | — | |
| SCHEMBL16172025 | 0.74 | TDP1 (0.39) | TDP1EYA2APPACEPHF8 | |
| SCHEMBL21778 | 0.72 | — | — | |
| SCHEMBL716553 | 0.72 | TDP1 (0.47) | TDP1EYA2APPACEPHF8 | |
| SCHEMBL7055782 | 0.72 | — | — | |
| SCHEMBL8587011 | 0.72 | — | — | |
| Glycine SCHEMBL5260202 | 0.72 | GLRA1 (0.37) | KDM4E | |
| SCHEMBL13386668 | 0.72 | MEN1 (0.32) | MEN1KMT2ATSHRCYP2C19LMNA | |
| SCHEMBL10256732 | 0.72 | MVD (0.44) | TDP1EYA2APPACEPHF8 | |
| SCHEMBL19449166 | 0.71 | POLB (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7232817-B2 | α- and β-amino acid hydroxyethlamino sulfonyl urea derivatives useful as retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2007-06-19 | — | — | US | disclosed |
| US-20060094789-A1 | Alpha- and beta-amino acid hydroxyethylamino sulfonyl urea derivatives useful as retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2006-05-04 | — | — | US | disclosed |
| US-7030161-B2 | α-and β-amino acid hydroxyethylamino sulfonyl urea derivatives useful as retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2006-04-18 | — | — | US | disclosed |
| US-6683648-B2 | ENZYME INHIBITORS SUCH AS 2S-(((DIMETHYLAMINO)ACETYL)AMINO)-N-(3-((((2-HYDROXY-1,1 -DIMETHYLETHYL)AMINO)SULFONYL)(3-METHYL BUTYL)AMINO)-2R-HYDROXY-1S-(PHENYLMETHYL)-PROPYL)-3,3-DIMETHYL BUTANAMIDE, USED FOR PROHYLAXIS OF VIRAL DISEASES | G. D. SEARLE & CO. | 2004-01-27 | — | — | US | disclosed |
| US-6403585-B1 | INHIBITING RETROVIRAL PROTEASES SUCH AS HUMAN IMMUNODEFICIENCY VIRUS (HIV) PROTEASE | G. D. SEARLE & CO. | 2002-06-11 | — | — | US | disclosed |
| US-6211176-B1 | AIDS TREATMENT | G. D. SEARLE & CO. | 2001-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094789-A1 | Alpha- and beta-amino acid hydroxyethylamino sulfonyl urea derivatives useful as retroviral protease inhibitors | DNPEP, PEPD, PREP | MEN1 4117/4885HTT 353/4885KMT2A 1216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.